FelicaMed Announced MARA Approval of Lirucitinib

In October 2024, MingMed Biotechnology Co., Ltd. (“MingMed”) announced that its subsidiary, FelicaMed Biotechnology Co., Ltd. ("FelicaMed"), primarily leading the research and development of

More
The World’s First Clinical Trial on Therapeutic Indication of Recombinant Botulinum Toxin Type A (YY001-002) Receives CDE approval

The World’s First Clinical Trial on Therapeutic Indication of Recombinant Botulinum Toxin Type A (YY001-002) Receives CDE approval

GUANGZHOU, July 5th, 2024 -- MingMed Biotechnology Co., Ltd today announced that its subsidiary, Cla...

FelicaMed Announced MARA Approval of Lirucitinib

FelicaMed Announced MARA Approval of Lirucitinib

In October 2024, MingMed Biotechnology Co., Ltd. (“MingMed”) announced that its subsidiary, FelicaMe...

Coming soon